Abbott Laboratories (ABT) operating KPIs
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Worldwide Revenue ($M) ($M)
Legacy standalone subsegment reported from Q4 2017 (post-Alere acquisition) through Q4 2025.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Worldwide Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,454 | -18.1% | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | 2,997 | -18.8% | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | 3,690 | -63.3% | SEC Filing (0001628280-25-002092) ↗ |
| FY2022 | Dec 31, 2022 | 10,061 | +17.6% | SEC Filing (0001628280-24-002009) ↗ |
| FY2021 | Dec 31, 2021 | 8,553 | +95.5% | SEC Filing (0001628280-23-001516) ↗ |
| FY2020 | Dec 31, 2020 | 4,376 | +113.0% | SEC Filing (0001104659-21-007942) ↗ |
| FY2019 | Dec 31, 2019 | 2,054 | -0.9% | SEC Filing (0001104659-20-005717) ↗ |
| FY2018 | Dec 31, 2018 | 2,072 | +283.7% | SEC Filing (0001104659-19-002848) ↗ |
| FY2017 | Dec 31, 2017 | 540 | – | SEC Filing (0001104659-18-003691) ↗ |
Breakdown
What makes up rapid diagnostics (legacy standalone subsegment through fy2025q4 — id now, binaxnow, panbio) — worldwide revenue ($m)
- Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Organic / Comparable Sales Growth (%)-18.0% · FY2025
- Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Reported Sales Growth (%)-18.1% · FY2025
- Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Foreign Exchange Impact on Sales Growth (%)-0.1% · FY2025
- Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — U.S. Revenue ($M)1,538 · FY2025
- Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — International Revenue ($M)916 · FY2025
- Rapid Diagnostics — Organic Sales Growth Excl. COVID-19 Testing (%)6.0% · FY2024
- Rapid Diagnostics — COVID-19 Testing Sales ($M)725 · FY2024
Cite this data
StockData. (2026). Abbott Laboratories Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Worldwide Revenue ($M) ($M), annual FY2017–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-rapid-leg-rev-ww
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.